@article{0b83c5033da3463abf71a29bb9ae23dd,
title = "Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era",
author = "Ciotti, {John R.} and Elena Grebenciucova and Moss, {Brandon P.} and Newsome, {Scott D.}",
note = "Funding Information: J.R.C.: funded by a Sylvia Lawry Physician Fellowship grant, the National Multiple Sclerosis Society; E.G.: nothing to report; B.P.M.: research funding for investigator‐initiated studies, Roche; site Principal Investigator for studies sponsored by Roche; speaking fees, Genzyme; consulting fees, Roche; owns stock, Pfizer; S.D.N.: scientific advisory boards, Biogen, Genentech, Celgene, Novartis, Greenwich Biosciences, EMD Serono; clinical trial clinical adjudication committee member, BioIncept, Autobahn Therapeutics, medDay Pharmaceuticals; grant/research funding (paid directly to institution), Biogen, Genentech, National Multiple Sclerosis Society, Department of Defense, and Patient Centered Outcomes Institute.",
year = "2020",
month = dec,
doi = "10.1002/ana.25907",
language = "English (US)",
volume = "88",
pages = "1062--1064",
journal = "Annals of neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",
}